ClinicalTrials.gov
public full text
Public Domain
Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration
The purpose of the project is to investigate in eyes with dry AMD, the efficacy and safety as preventive therapy of the immunomodulatory substance named copaxone which had been proven as safe and effective agent for a neurodegenerative disease, in arresting the progression as well as the conversion of dry AMD to wet AMD. The hypothesis that the immunomodulatory agent copaxone proven for a neurodegenerative disease may work in the eye is revolutionary and may open a new avenue of preventive treatment for the disease which is the major cause of legal blindness in the industrial world
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Copaxone in Age Related Macular Degeneration#967990
- BMBF-Förderprojekt "Nanofunktionale Hydrogele", Teilprojekt "Retina-Patch" : Schlussbericht#675000
- Safety Evaluation Study of Pitavastatin PLGA Nano-particle for Retinitis Pigmentosa#1032581
- Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD#913086
- The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD)#1139709
Record · ID 896833
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive